BillionToOne Targets Oncology Selection And Monitoring

This move shifts BillionToOne from a fast growing prenatal lab into a head to head fight with oncology platforms that already sit inside cancer treatment decisions. In oncology, winning is not just about running a blood test. It means getting oncologists to use one assay to pick a drug, then keep using another assay to track whether the tumor is shrinking, recurring, or evolving, and it means doing that with Medicare coverage, clinical validation, and hospital workflow fit.

• BillionToOne is building a two product oncology workflow. Northstar Select is its blood based panel for therapy selection in advanced solid tumors, and Northstar Response is its tissue free monitoring test. That puts it directly against Guardant in therapy selection and against Natera and Myriad in ongoing blood based monitoring, especially MRD and treatment response use cases.
  1 billiontoone 2 billiontoone 6 sacra 7 guardanthealth
• The incumbents come in with different strengths. Guardant leads with broad adoption in comprehensive genomic profiling and a large commercial footprint around Guardant360. Natera has built strong clinician mindshare in serial monitoring through Signatera. Myriad is pushing deeper into oncology with Precise MRD and a broader cancer testing sales base. BillionToOne is smaller, but is trying to win on assay sensitivity and a simpler blood only workflow.
  3 sacra 4 guardanthealth 5 myriad 6 sacra 7 guardanthealth
• The bar is also much higher than in prenatal testing. BillionToOne has already won Medicare coverage for Northstar Select, and its company materials position the oncology business around therapy selection plus response monitoring. That is the minimum needed to compete in a market where reimbursement, published validation, and repeat physician use matter as much as raw lab accuracy.
  1 billiontoone 2 billiontoone 3 sacra

The likely path forward is a bundled oncology business where one blood draw helps choose treatment and later blood draws show whether it is working. If BillionToOne can turn its sensitivity advantage into repeat ordering behavior, it can expand from a prenatal specialist into a broader precision diagnostics company with much larger revenue per patient and much deeper clinical integration.